Skip to content

Study · Animal study (in vivo) · mouse · 2018

5 results

Linaclotide improves gastrointestinal transit in cystic fibrosis mice by inhibiting sodium/hydrogen exchanger 3.

McHugh DR, Cotton CU, Moss FJ, Vitko M, Valerio DM, Kelley TJ, Hao S, Jafri A, Drumm ML, Boron WF, Stern RC, McBennett K, Hodges CA

American journal of physiology. Gastrointestinal and liver physiology17 Aug 2018Cited by 28 (Europe PMC)

PMID30118317 (opens in a new tab)PMCIDPMC9925117 (opens in a new tab)DOI10.1152/ajpgi.00261.2017 (opens in a new tab)PepBankPUB-30118317
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In CF mice carrying F508del or null Cftr mutations, linaclotide improved intestinal transit.

    In plain wordsIn mice with CF, linaclotide improved intestinal transit.

    Peptide
    Linaclotide
    Outcome
    IncreaseIntestinal transit
    Study

    mousen: not reported in source

    CF mouse models
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Linaclotide treatment improved intestinal transit in mice carrying either F508del or null Cftr mutations but did not induce detectable Cl- secretion.
    1 context sentence
    Summary · context
    The goal of this study was to determine the effectiveness and mechanism of linaclotide in treating CF gastrointestinal disorders using CF mouse models. Intestinal transit, chloride secretion, and intestinal lumen fluidity were assessed in wild-type and CF mouse models in response to linaclotide.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In CF mice, linaclotide did not induce detectable chloride secretion.

    In plain wordsIn mice with CF, linaclotide did not induce detectable chloride secretion.

    Peptide
    Linaclotide
    Outcome
    No significant changeChloride secretion
    Study

    mousen: not reported in source

    CF mouse models
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Linaclotide treatment improved intestinal transit in mice carrying either F508del or null Cftr mutations but did not induce detectable Cl- secretion.
    1 context sentence
    Summary · context
    The goal of this study was to determine the effectiveness and mechanism of linaclotide in treating CF gastrointestinal disorders using CF mouse models. Intestinal transit, chloride secretion, and intestinal lumen fluidity were assessed in wild-type and CF mouse models in response to linaclotide.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In CF mice, linaclotide increased intestinal fluid retention.

    In plain wordsIn mice with CF, linaclotide increased intestinal fluid retention.

    Peptide
    Linaclotide
    Outcome
    IncreaseIntestinal fluid retention
    Study

    mousen: not reported in source

    CF mouse models
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Linaclotide increased fluid retention and fluidity of CF intestinal contents, suggesting inhibition of fluid absorption.
    1 context sentence
    Summary · context
    The goal of this study was to determine the effectiveness and mechanism of linaclotide in treating CF gastrointestinal disorders using CF mouse models. Intestinal transit, chloride secretion, and intestinal lumen fluidity were assessed in wild-type and CF mouse models in response to linaclotide.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In CF mice, linaclotide increased intestinal content fluidity.

    In plain wordsIn mice with CF, linaclotide increased intestinal content fluidity.

    Peptide
    Linaclotide
    Outcome
    IncreaseIntestinal content fluidity
    Study

    mousen: not reported in source

    CF mouse models
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Linaclotide increased fluid retention and fluidity of CF intestinal contents, suggesting inhibition of fluid absorption.
    1 context sentence
    Summary · context
    The goal of this study was to determine the effectiveness and mechanism of linaclotide in treating CF gastrointestinal disorders using CF mouse models. Intestinal transit, chloride secretion, and intestinal lumen fluidity were assessed in wild-type and CF mouse models in response to linaclotide.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In CF mice, linaclotide and tenapanor produced similar improvements in gastrointestinal transit.

    In plain wordsIn mice with CF, linaclotide and tenapanor produced similar transit improvements.

    Peptide
    Linaclotide
    Outcome
    Direction not reportedGastrointestinal transit versus tenapanor
    Study

    mousen: not reported in source

    CF mouse models
    Comparator
    tenapanor
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Targeted inhibition of sodium absorption by the NHE3 inhibitor tenapanor produced improvements in gastrointestinal transit similar to those produced by linaclotide treatment, suggesting that inhibition of fluid absorption by linaclotide contributes to improved gastrointestinal transit in CF.
    1 context sentence
    Summary · context
    The goal of this study was to determine the effectiveness and mechanism of linaclotide in treating CF gastrointestinal disorders using CF mouse models. Intestinal transit, chloride secretion, and intestinal lumen fluidity were assessed in wild-type and CF mouse models in response to linaclotide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingEarly phase 1NCT07569419

Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis

University of Nottinghamn = 269 Mar 2026 to est. Oct 2026

Cystic Fibrosis (CF)

Trial pageClinicalTrials.govUpdated 6 May 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.